

REVIEW ARTICLE | OPEN ACCESS

Anesthetic conditioning for ischemic stroke: from bench to bedside

Yunlu Guo¹, Peiying Li^{1*}

Ischemic stroke is a leading cause of cognitive dysfunction, morbidity and death, causing an ever-increasing burden to society. It is therefore of great clinical value and significance to find medications that are efficacious outside the therapeutic window of current treatments for long-term neuroprotection. Anesthetic postconditioning (PostC) is a promising strategy against ischemic stroke. In this mini-review, we summarized the protective mechanisms underlying anesthetic PostC, including excitotoxicity inhibition, anti-inflammation, anti-oxidation, signal transduction, and cell death inhibition. We also raised a few issues that need to be resolved before successful translation into the clinic, such as the time window, the risks, and the impact of gender, age, and comorbidities. We conclude that prospective randomized controlled trials are highly warranted to pave the way for the clinical translation of anesthetic PostC in treating ischemic stroke patients for long-term neuroprotection.

Keywords: ischemic stroke, anesthetics, postconditioning, neuroprotection

Ischemic stroke is a leading cause of cognitive dysfunction, morbidity and death. With a global incidence of 9.5 million events and a lifetime risk of 18.3% in 2016 (Feigin et al., 2018; 2019), ischemic stroke is causing a great and increasing burden to society. So far, only thrombolysis with tissue plasminogen activator (t-PA) and mechanical thrombectomy have been approved by the Food and Drug Administration to treat acute ischemic stroke. However, the above treatments are still limited by the short therapeutic time window (Wechsler and Jovin, 2012) and the increased risk of hemorrhagic transformation (Camara et al., 2021). It is of great clinical value and significance to find medications outside the therapeutic window of the above acute treatments for long-term neuroprotection.

Ischemic conditioning refers to one or more brief episodes of non-lethal hypoperfusion to protect organs against a lethal ischemic insult (Murry et al., 1986; Hausenloy and Yellon, 2011). It can be classified into ischemic pre-conditioning (IPreC), per-conditioning (IPeC), or post-conditioning (IPostC) according to whether the treatment precedes, occurs during, or after the stroke ischemia or reperfusion time points (Wang et al., 2015c). The concept of conventional IPostC has been

extended to the more feasible remote IPostC (Weir et al., 2021) and chemical PostC with carbon dioxide and anesthetics, for example (Fan et al., 2017). Notably, several anesthetic agents can reduce cerebral blood flow (CBF), decrease the cerebral metabolic rate of oxygen (CMRO₂) and show neuroprotective effects, such as intravenous anesthetics (propofol, etomidate, dexmedetomidine, benzodiazepines) and volatile anesthetics (isoflurane, sevoflurane and desflurane) (Slupe and Kirsch, 2018). These are thought to be capable of inducing conditioning, which is termed “anesthetic conditioning” (Wang et al., 2016a). Since most cerebrovascular events are unpredictable, anesthetic PostC could provide more opportunities for therapeutic intervention and is more applicable compared to anesthetic pre-conditioning (Zhao, 2007). In this short review, we will focus on the translation of anesthetic PostC from bench to bedside, review laboratory and clinical studies to evaluate the effects of anesthetics after reperfusion of ischemic stroke, and discuss limitations and feasibility of anesthetic PostC.

In the rodent ischemic stroke model using filament occlusion, anesthetic treatment was reported to reduce neurological injury (infarct volume and neurological deficit score combined) by

¹Department of Anesthesiology, State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, School of Medicine Shanghai Jiao Tong University, Shanghai, China.

*Correspondence should be addressed to Dr. Peiying Li, MD, PhD (peiyingli.md@gmail.com).

Table 1. Summary of representative studies on anesthetic PostC for ischemic stroke

Author	Anesthetic agent	Species	Ischemia model	Interval after I/R	Effective Dose	Treatment period	Molecular mechanism
Lee et al., 2008	Isoflurane	SD rats	OGD 15 min MCAO 90 min	0 s, 10 min 0 s	2% 2%	30 min 60 min	mK ⁺ _{ATP} involved
Li et al., 2013	Isoflurane	SD rats C57BL/6J mice	MCAO 90 min MCAO 90 min	0 s 0 s	2% 2%	60 min 60 min	NF-κB↓, IL-6↓, IL-1β↓
Wang et al., 2016b	Isoflurane	SD rats	MCAO 90 min	0 s	1.5%, 3.0%	60 min	TGF-β1↑, p-Smad2/3↑, p-JNK↓
Yuan et al., 2018	Isoflurane	SD rats	MCAO 90 min	0 s	1.5%	60 min	BMP4/Smad1/5/8 pathway↑, AQP-4↓
Peng et al., 2019a	Isoflurane	SD rats	MCAO 90 min	0 s	1.5%	60 min	VEGF and CD34↑ through Shh pathway
Peng et al., 2019b	Isoflurane	SD rats	MCAO 90 min	0 s	1.5%	60 min	TGF-β2/Smad3 pathway↑, VEGF and CD34↑
Yin et al., 2020	Isoflurane	SD rats	MCAO 90 min	0 s	1.5%	60 min	TGF-β1/Smad2/3 pathway↑, p-Cx43↑
Dong et al., 2014	Sevoflurane	F344 rats	MCAO 120 min	0 s	2.6%	15 min	Bcl-2↑, Bax↓
Li et al., 2014	Sevoflurane	SD rats	MCAO 60 min	0 s	2.6%	60 min	Akt/Nrf2 pathway↑, NQO1 and HO-1↑
Wang et al., 2015b	Sevoflurane	SD rats	MCAO 90 min	0 s	1.0 MAC	30 min	mK ⁺ _{ATP} activation, mPTP opening inhibited
Zhu et al., 2017	Sevoflurane	SD rats	MCAO 90 min	0 s	2.5%	90 min	GFAP, neurocan and phosphacan↓, cathB↓
Wang et al., 2009	Propofol	SD rats	MCAO 120 min	0 s	10, 20 mg/kg/h	30 min	PI3K/Akt pathway↑
Wang et al., 2011	Propofol	SD rats	MCAO 60 min	0 s	20 mg/kg/h	240 min	surface AMPAR GluR2 subunit↑
Liang et al., 2013	Propofol	SD rats	MCAO 90 min	0 s	20, 50 mg/kg/h	30 min	HO-1↑
Ji et al., 2015	Propofol	Wistar rats	MCAO 120 min	0 s	20, 40 mg/kg/h	30 min	MMP-9, AQP-4 and pJNK↓
Wang et al., 2015a	Propofol	SD rats	MCAO 60 min	0 s	20 mg/kg/h	120 min	KCC2 in GABAergic interneurons↑
Luo et al., 2017	Dexmedetomidine	C57BL/6 mice	OGD 360 min MCAO 90 min	0 s 0 s	1 μM 25 μg/kg i.p.	240 min -	Inhibition of neuronal autophagy by HIF-1α↑

I/R, ischemia/reperfusion; OGD, oxygen-glucose deprivation; MCAO, middle cerebral artery occlusion; MAC, minimal alveolar concentration; i.p., intraperitoneal injection; mK⁺_{ATP}, mitochondrial ATP-dependent potassium channels; NF-κB, nuclear factor kappa-B; TGF-β, transforming growth factor beta; p-JNK, phosphorylated c-Jun N-terminal kinase; BMP4, bone morphogenetic protein 4; AQP-4, aquaporin-4; VEGF, vascular endothelial growth factor; Shh, sonic hedgehog; Cx43, connexin 43; Bcl-2, B-cell lymphoma-2; Bax, BCL-associated X protein; Akt, protein kinase B; Nrf2, nuclear factor-erythroid 2-related factor-2; NQO1, quinone oxidoreductase1; HO-1, hemeoxygenase-1; mPTP, mitochondrial permeability transition pore; GFAP, glial fibrillary acidic protein; CathB, cathepsin B; PI3K, phosphoinositide-3-kinase; AMPAR, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; MMP-9, matrix metalloproteinase-9; KCC2, K⁺-Cl⁻-co-transporter 2; HIF-1α, hypoxia inducible factor-1α

28% with considerable heterogeneity according to a systemic review of 80 studies (Archer et al., 2017). Isoflurane and sevoflurane PostC, which were the most studied agents, have been shown to alleviate ischemia/reperfusion (I/R) injury and improve short and long-term neurological outcomes in the middle cerebral artery occlusion (MCAO) model (Lee et al., 2008; Li et al., 2013; Dong et al., 2014; Li et al., 2014; Wang et al., 2015b; Wang et al., 2016b; Zhu et al., 2017; Yuan et al., 2018; Peng et al., 2019a; Peng et al., 2019b; Yin et al., 2020). In addition, propofol and dexmedetomidine injection can attenuate cerebral I/R injury and induce neuroprotection in focal ischemia (Wang et al., 2009; Wang et al., 2011; Liang et al., 2013; Ji et al., 2015; Wang et al., 2015a; Luo et al., 2017). Similar to other kinds of PostC, neuroprotection by anesthetic PostC is concentration-dependent and time-dependent. For example, 1.5-3.0%, i.e. 1-2 minimal alveolar concentration (MAC) isoflurane posttreatment for 60 min at the start of reperfusion can protect against brain injury, while 4.5% isoflurane failed to show similar effects (Wang et al., 2016b). The protective effects of propofol on neurological deficits, infarct volume, and neuronal apoptosis are dose-dependent, which all reach statistical

significance at a dose of 20 mg/kg/h (Liang et al., 2013). However, the therapeutic time window of these anesthetics against ischemic stroke should be further investigated as the treatments were generally only given at the onset of reperfusion in the above studies (Table 1).

In terms of protective mechanisms, anesthetic PostC can decrease brain infarct volume, reduce neuronal death, attenuate reactive astrogliosis (Zhu et al., 2017), inhibit brain edema (Yuan et al., 2018), protect the blood brain barrier (Ji et al., 2015), enhance angiogenesis (Peng et al., 2019a), and improve neurological function in experimental stroke models in rodents (Table 1). However, although the protective mechanisms of multi-target anesthetic PostC are not completely understood, there are some molecular mechanisms frequently studied, including regulation of synaptic signaling, anti-inflammation, inhibition of mitochondrial damage, anti-oxidation, activation of the phosphoinositide-3-kinase/ protein kinase B (PI3K/Akt) pathway, and anti-apoptosis (Archer et al., 2017; Fan et al., 2017). We summarize the interrelated protective mechanisms underlying the anesthetic PostC as follows (Figure 1):

a) Anesthetics protect synaptic function by regulating




Figure 1. The schematic represents major neuroprotective mechanisms of anesthetic PostC. The 6 protective mechanisms underlying anesthetic PostC and the corresponding molecules and pathways are listed in the scheme. The above 5 mechanisms (synaptic signaling regulation, anti-inflammation, mitochondrial damage inhibition, anti-oxidation, signal transduction pathway) can indirectly reduce neuronal apoptosis. Together, these molecular mechanisms lead to inhibition of brain infarction, brain edema, neuronal death and BBB damage, with promotion of neurological functions. GABA, γ -aminobutyric acid; AMPAR, α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; TNF- α , tumor necrosis factor- α ; iNOS, inducible nitric oxide synthase; NF- κ B, nuclear factor kappa-B; TGF- β , transforming growth factor beta 1; mPTP, mitochondrial permeability transition pore; mK⁺_{ATP}, mitochondrial ATP-dependent potassium channels; Akt, protein kinase B; Nrf2, nuclear factor-erythroid 2-related factor-2; NQO1, quinone oxidoreductase1; HO-1, hemeoxygenase-1; JNK, c-Jun N-terminal kinase; PI3K, phosphoinositide-3-kinase; AQP-4, aquaporin-4; MMP-9, matrix metalloproteinase-9; Cx43, connexin 43; VEGF, vascular endothelial growth factor; Bcl-2, B-cell lymphoma-2; Bax, BCL-associated X protein; ROS, reactive oxygen species; BBB, blood brain barrier.

the content of neurotransmitters to prevent excitotoxicity. PostC with sevoflurane was shown to reduce neuronal injury after oxygen-glucose deprivation (OGD)-reperfusion in rat hippocampal slices, *in vitro*, with a decrease in excitatory amino acids (aspartate, glutamate) and a significant increase in the inhibitory neurotransmitter γ -aminobutyric acid (GABA) (Peng et al., 2011). Propofol PostC can provide short-term (24 h) neuroprotection by increasing K⁺-Cl⁻-co-transporter 2 (KCC2) expression in GABAergic interneurons (Wang et al., 2015a), and induce long-term (up to 28 days) neuroprotection by inhibiting internalization of the α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptor GluR2 subunit (Wang et al., 2011).

b) Anesthetics can reduce secondary neuroinflammation. As shown in volatile anesthetics, the proinflammatory factors interleukin (IL)-1 β , IL-6, tumor necrosis factor- α (TNF- α), inducible nitric oxide synthase (iNOS), and nuclear factor kappa-B (NF- κ B) are down-regulated (Li et al., 2013), whereas the anti-inflammatory transforming growth factor beta 1 (TGF- β 1) is up-regulated (Archer et al., 2017).

c) Mitochondria-based mechanisms may play an important role in the neuroprotection against stroke. The process of mitochondrial damage causes mitochondrial swelling, reactive oxygen species (ROS) overproduction, and release of proapoptotic molecules. Isoflurane or sevoflurane PostC can inhibit the opening of mitochondrial permeability transition pore (mPTP) located in the inner mitochondrial membrane, which may be related to mitochondrial ATP-dependent potassium channels (mK⁺_{ATP}) opening (Wang et al., 2015b).

d) Anti-oxidation against ROS generated after stroke could inhibit oxidative stress. Inhibition of mitochondrial damage and anti-oxidation mechanisms both reduce ROS

production. Sevoflurane PostC can protect the brain through up-regulation of the Akt/nuclear factor-erythroid 2-related factor-2 (Nrf2) pathway, in which Akt phosphorylation facilitates the translocation of transcription factor Nrf2, then Nrf2 binds to the antioxidant response element (ARE) and induces expression of antioxidant enzymes such as quinone oxidoreductase1 (NQO1) and hemeoxygenase-1 (HO-1) (Li et al., 2014). Propofol can also increase HO-1 protein expression (Liang et al., 2013).

e) PI3K/Akt and other pathways are important in signal transduction and cell survival. The propofol PostC effect is mediated partly by maintaining the activity of the PI3K/Akt pathway (Wang et al., 2009). Besides PI3K/Akt pathway, the mitogen-activated protein kinase (MAPK) and transforming growth factor beta (TGF β)/SMAD pathways have also been studied. The MAPK pathways include c-Jun N-terminal kinase (JNK) and extracellular signal-regulated protein kinase (ERK) 1/2. Isoflurane at 1.5% can upregulate the expression of TGF- β 1 and downregulate phosphorylated JNK to mitigate cerebral injury (Wang et al., 2016b). The underlying mechanism of propofol PostC involves inhibition of aquaporin-4 (AQP-4), matrix metalloproteinase-9 (MMP-9), and phosphorylation of JNK (Ji et al., 2015). Dexmedetomidine PostC also inhibits JNK pathway activation to reduce the inflammatory response and autophagy effect (Zhu et al., 2019). For the TGF β /SMAD pathways, isoflurane PostC can upregulate phosphorylated connexin 43 in gap junctions through the TGF- β 1/Smad2/3 signaling pathway (Yin et al., 2020), downregulate AQP-4 to inhibit brain edema through the bone morphogenetic protein 4 (BMP4)/Smad1/5/8 pathway (Yuan et al., 2018), and can increase the expression of vascular endothelial growth factor (VEGF) and CD34 related to angiogenesis by activating the TGF- β 2/Smad3 pathway (Peng et al., 2019b). In addition,

isoflurane PostC reduced cerebral injury by enhancing angiogenesis through the sonic hedgehog (Shh)/Gli signaling pathway (Peng et al., 2019a).

f) Anti-apoptosis of neurons is related to the rescue of ischemic penumbra areas. Anesthetic PostC could reduce apoptosis by up-regulating the anti-apoptosis protein B-cell lymphoma-2 (Bcl-2), which is a downstream protein of the PI3K/Akt pathway, and by down-regulating the pro-apoptotic BCL-associated X protein (Bax) (Dong et al., 2014). The above 5 mechanisms (inhibition of excitotoxicity, anti-inflammation, inhibition of mitochondrial damage, anti-oxidation, and signal transduction) can also indirectly reduce neuronal apoptosis.

Among the above neuroprotective mechanisms, signal transduction is the most frequently studied one. Alteration in signal transduction could also influence other molecular mechanisms of anesthetic PostC. The key mechanisms shown to be causal related to PostC were confirmed in some pre-clinical studies using a selective PI3K inhibitor (Wang et al., 2009), JNK pathway blocker or activator (Wang et al., 2016b; Zhu et al., 2019), TGF- β 1 or TGF- β 2 inhibitor (Peng et al., 2019b; Yin et al., 2020), and Shh pathway inhibitor (Peng et al., 2019a). In addition, IL-1 β deficient mice (Li et al., 2013), a mK⁺_{ATP} blocker with mPTP opener (Wang et al., 2015b), and HO-1 inhibitor (Liang et al., 2013) were used to identify the causality of anti-inflammation, mitochondrial damage inhibition, and anti-oxidation mechanisms, respectively. The above evidence suggest that signal transduction, anti-inflammation, mitochondrial damage inhibition, and anti-oxidation may represent the key mechanisms that underlie the neuroprotection of PostC, while others may warrant further investigation.

Although several anesthetics have shown high neuroprotective potential in animal studies, there is still a lack of clinical data to support that PostC is protective in stroke patients at present. In nonrandomized studies, general anesthesia during thrombectomy for acute ischemic stroke was thought to be associated with poor outcome and high mortality (Abou-Chebl et al., 2015; van den Berg et al., 2015; Brinjikji et al., 2017; Campbell et al., 2018). However, a few relevant randomized controlled trials (RCT) showed different results. For instance, in the Sedation vs. Intubation for Endovascular Stroke Treatment (SIESTA; NCT02126085) trial, among 150 patients with acute ischemic stroke in the anterior circulation undergoing endovascular thrombectomy, conscious sedation (CS) compared with general anesthesia (GA) did not result in greater neurological improvement at 24 h or long-term functional recovery after 3 months. The peri-interventional feasibility and safety of GA were also comparable to that of sedation (Schönenberger et al., 2016). Furthermore, analysis of stroke patients in the General or Local Anesthesia in Intra Arterial Therapy (GOLIATH; NCT02317237) trial found that GA did not result in larger infarct growth or worse clinical outcomes compared to CS during endovascular therapy (Simonsen et al., 2018). In a meta-analysis of 3 single-center randomized clinical trials (SIESTA, Anesthesia During Stroke [ANSTROKE; NCT01872884] and GOLIATH), protocol-based GA was shown to be significantly associated with lower disability at 3 months (Schönenberger et al., 2019). A pooled analysis of three large prospective multi-center studies (SOLITAIRETM FR With the Intention For Thrombectomy [SWIFT; NCT01054560], Solitaire With the Intention For Thrombectomy as Primary Endovascular Treatment [SWIFT PRIME; NCT0165746] Solitaire FR Thrombectomy for Acute Revascularization [STAR; NCT01327989] trials) also showed that GA was related to a lower risk for hemorrhagic transformation after thrombectomy (Raychev et al., 2020). More high-quality clinical trials on the posttreatment of anesthetics are needed, especially in stroke patients undergoing thrombolysis.

As a clinically available treatment in hospitals, anesthetic

PostC has several advantages. For example, it can be performed simultaneously with thrombolysis and mechanical thrombectomy and the safety and accessibility of these widely used medications are guaranteed. In addition, timely anesthetic PostC may be suitable for perioperative stroke. To successfully translate laboratory results to the bedside, some issues or limitations need to be considered. 1) Comorbidities have influence on PostC mechanisms. Anesthetic neuroprotection failed in females, aged animals, and animals with comorbidities (diabetes, diet-induced obesity, high-fat diets) as the specific neuroprotective mechanisms are impaired (Kitano et al., 2007; Dong et al., 2014; Yang et al., 2014; Yu et al., 2014). Thus, young healthy male animals may not be an ideal model for human stroke. Replication of PostC effects in animals with comorbidities may significantly improve the translation of laboratory findings to the clinic (Archer et al., 2017). 2) The differences between the traditional MCAO model and human stroke are relatively large. As the reperfusion is performed with thrombolytics in the clinic, it's of more value to study in the embolic stroke model with t-PA (Fan et al., 2017; Wu et al., 2020), which is closer to ischemic stroke in human. 3) The therapeutic time window, choice of anesthetic agents, effective dose, duration, and the risks of anesthetic PostC need to be clarified in animal and human stroke studies.

As reviewed above, anesthetic PostC is a promising strategy against ischemic stroke. The protective mechanisms mainly include excitotoxicity inhibition, anti-inflammation, anti-oxidation, signal transduction, and cell death inhibition. However, a few issues should be resolved before successful translation into the clinic, such as the time window, risks, and the impact of gender, age, and comorbidities. Prospective randomized controlled trials are highly warranted to pave the way for the clinical translation of anesthetic PostC in treating ischemic stroke patients for long-term neuroprotection.

Acknowledgements

P.L. is supported by the National Natural Science Foundation of China (NSFC, 81722017, 91957111, 81971096, 82061130224), New Frontier Technology Joint Research sponsored by Shanghai Shengkang Hospital Development Center (SHDC12019102), Shanghai Municipal Education Commission-Gaofeng Clinical Medical Grant Support (20181805), Shuguang Program supported by Shanghai Education Development Foundation and Shanghai Municipal Education Commission (20SG17), and Shanghai Outstanding Academic Leaders' Program from Shanghai Municipal Science and Technology Committee (20XD1422400), Newton Advanced Fellowship grant provided by the UK Academy of Medical Sciences (NAF\R11\1010).

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the authorship, and/or publication of this article.

References

- (2019) Global, regional, and national burden of stroke, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *The Lancet Neurology* 18:439-458.
- Abou-Chebl A, Yeatts SD, Yan B, Cockroft K, Goyal M, Jovin T, Khatri P, Meyers P, Spilker J, Sugg R, Wartenberg KE, Tomsick T, Broderick J, Hill MD (2015) Impact of General Anesthesia on Safety and Outcomes in the Endovascular Arm of Interventional Management of Stroke (IMS) III Trial. *Stroke* 46:2142-2148.
- Archer DP, Walker AM, McCann SK, Moser JJ, Appireddy RM (2017) Anesthetic Neuroprotection in Experimental Stroke in Rodents: A Systematic Review and Meta-analysis.

- Anesthesiology 126:653-665.
- Brinjikji W, Pasternak J, Murad MH, Cloft HJ, Welch TL, Kallmes DF, Rabinstein AA (2017) Anesthesia-Related Outcomes for Endovascular Stroke Revascularization: A Systematic Review and Meta-Analysis. *Stroke* 48:2784-2791.
- Camara R, Matei N, Zhang JH (2021) Evolution of the stroke paradigm: A review of delayed recanalization. *Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism* 41:945-957.
- Campbell BCV et al. (2018) Effect of general anaesthesia on functional outcome in patients with anterior circulation ischaemic stroke having endovascular thrombectomy versus standard care: a meta-analysis of individual patient data. *The Lancet Neurology* 17:47-53.
- Dong P, Zhao J, Zhang Y, Dong J, Zhang L, Li D, Li L, Zhang X, Yang B, Lei W (2014) Aging causes exacerbated ischemic brain injury and failure of sevoflurane post-conditioning: role of B-cell lymphoma-2. *Neuroscience* 275:2-11.
- Fan YY, Hu WW, Nan F, Chen Z (2017) Postconditioning-induced neuroprotection, mechanisms and applications in cerebral ischemia. *Neurochemistry international* 107:43-56.
- Feigin VL et al. (2018) Global, Regional, and Country-Specific Lifetime Risks of Stroke, 1990 and 2016. *The New England journal of medicine* 379:2429-2437.
- Hausenloy DJ, Yellon DM (2011) The therapeutic potential of ischemic conditioning: an update. *Nature reviews Cardiology* 8:619-629.
- Ji FT, Liang JJ, Miao LP, Wu Q, Cao MH (2015) Propofol post-conditioning protects the blood brain barrier by decreasing matrix metalloproteinase-9 and aquaporin-4 expression and improves the neurobehavioral outcome in a rat model of focal cerebral ischemia-reperfusion injury. *Molecular medicine reports* 12:2049-2055.
- Kitano H, Young JM, Cheng J, Wang L, Hurn PD, Murphy SJ (2007) Gender-specific response to isoflurane preconditioning in focal cerebral ischemia. *Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism* 27:1377-1386.
- Lee JJ, Li L, Jung HH, Zuo Z (2008) Postconditioning with isoflurane reduced ischemia-induced brain injury in rats. *Anesthesiology* 108:1055-1062.
- Li B, Sun J, Lv G, Yu Y, Wang G, Xie K, Jiao Y, Yu Y (2014) Sevoflurane postconditioning attenuates cerebral ischemia-reperfusion injury via protein kinase B/nuclear factor-erythroid 2-related factor 2 pathway activation. *International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience* 38:79-86.
- Li H, Yin J, Li L, Deng J, Feng C, Zuo Z (2013) Isoflurane postconditioning reduces ischemia-induced nuclear factor- κ B activation and interleukin 1 β production to provide neuroprotection in rats and mice. *Neurobiology of disease* 54:216-224.
- Liang C, Cang J, Wang H, Xue Z (2013) Propofol attenuates cerebral ischemia/reperfusion injury partially using heme oxygenase-1. *Journal of neurosurgical anesthesiology* 25:311-316.
- Luo C, Ouyang MW, Fang YY, Li SJ, Zhou Q, Fan J, Qin ZS, Tao T (2017) Dexmedetomidine Protects Mouse Brain from Ischemia-Reperfusion Injury via Inhibiting Neuronal Autophagy through Up-Regulating HIF-1 α . *Frontiers in cellular neuroscience* 11:197.
- Murry CE, Jennings RB, Reimer KA (1986) Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. *Circulation* 74:1124-1136.
- Peng L, Yin J, Ge M, Wang S, Xie L, Li Y, Si JQ, Ma K (2019a) Isoflurane Post-conditioning Ameliorates Cerebral Ischemia/Reperfusion Injury by Enhancing Angiogenesis Through Activating the Shh/Gli Signaling Pathway in Rats. *Frontiers in neuroscience* 13:321.
- Peng L, Yin J, Wang S, Ge M, Han Z, Wang Y, Zhang M, Xie L, Li Y (2019b) TGF- β 2/Smad3 Signaling Pathway Activation Through Enhancing VEGF and CD34 Ameliorates Cerebral Ischemia/Reperfusion Injury After Isoflurane Post-conditioning in Rats. *Neurochemical research* 44:2606-2618.
- Peng S, Kalikiri P, Mychaskiw G, 2nd, Zhang D, Zhang Y, Liu GJ, Wang GL, Shen ZY (2011) Sevoflurane postconditioning ameliorates oxygen-glucose deprivation-reperfusion injury in the rat hippocampus. *CNS neuroscience & therapeutics* 17:605-611.
- Raychev R, Saver JL, Jahan R, Nogueira RG, Goyal M, Pereira VM, Gralla J, Levy EI, Yavagal DR, Cognard C, Liebeskind DS (2020) The impact of general anesthesia, baseline ASPECTS, time to treatment, and IV tPA on intracranial hemorrhage after neurothrombectomy: pooled analysis of the SWIFT PRIME, SWIFT, and STAR trials. *Journal of neurointerventional surgery* 12:2-6.
- Schönenberger S, Uhlmann L, Hacke W, Schieber S, Mundiyanapurath S, Purrucker JC, Nagel S, Klose C, Pfaff J, Bendzus M, Ringleb PA, Kieser M, Möhlenbruch MA, Bösel J (2016) Effect of Conscious Sedation vs General Anesthesia on Early Neurological Improvement Among Patients With Ischemic Stroke Undergoing Endovascular Thrombectomy: A Randomized Clinical Trial. *Jama* 316:1986-1996.
- Schönenberger S, Hendén PL, Simonsen CZ, Uhlmann L, Klose C, Pfaff JAR, Yoo AJ, Sørensen LH, Ringleb PA, Wick W, Kieser M, Möhlenbruch MA, Rasmussen M, Rentzos A, Bösel J (2019) Association of General Anesthesia vs Procedural Sedation With Functional Outcome Among Patients With Acute Ischemic Stroke Undergoing Thrombectomy: A Systematic Review and Meta-analysis. *Jama* 322:1283-1293.
- Simonsen CZ, Yoo AJ, Sørensen LH, Juul N, Johnsen SP, Andersen G, Rasmussen M (2018) Effect of General Anesthesia and Conscious Sedation During Endovascular Therapy on Infarct Growth and Clinical Outcomes in Acute Ischemic Stroke: A Randomized Clinical Trial. *JAMA neurology* 75:470-477.
- Slupe AM, Kirsch JR (2018) Effects of anesthesia on cerebral blood flow, metabolism, and neuroprotection. *Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism* 38:2192-2208.
- van den Berg LA, Koelman DL, Berkhemer OA, Rozeman AD, Franssen PS, Beumer D, Dippel DW, van der Lugt A, van Oostenbrugge RJ, van Zwam WH, Brouwer PA, Jenniskens S, Boiten J, Lycklama À Nijeholt GA, Vos JA, Schonewille WJ, Majoie CB, Roos YB (2015) Type of anesthesia and differences in clinical outcome after intra-arterial treatment for ischemic stroke. *Stroke* 46:1257-1262.
- Wang H, Luo M, Li C, Wang G (2011) Propofol post-conditioning induced long-term neuroprotection and

- reduced internalization of AMPAR GluR2 subunit in a rat model of focal cerebral ischemia/reperfusion. *Journal of neurochemistry* 119:210-219.
- Wang H, Liu S, Wang H, Wang G, Zhu A (2015a) The effect of propofol postconditioning on the expression of K(+)-Cl(-)-co-transporter 2 in GABAergic inhibitory interneurons of acute ischemia/reperfusion injury rats. *Brain research* 1597:210-219.
- Wang H, Li P, Xu N, Zhu L, Cai M, Yu W, Gao Y (2016a) Paradigms and mechanisms of inhalational anesthetics mediated neuroprotection against cerebral ischemic stroke. *Medical gas research* 6:194-205.
- Wang HY, Wang GL, Yu YH, Wang Y (2009) The role of phosphoinositide-3-kinase/Akt pathway in propofol-induced postconditioning against focal cerebral ischemia-reperfusion injury in rats. *Brain research* 1297:177-184.
- Wang JK, Wu HF, Zhou H, Yang B, Liu XZ (2015b) Postconditioning with sevoflurane protects against focal cerebral ischemia and reperfusion injury involving mitochondrial ATP-dependent potassium channel and mitochondrial permeability transition pore. *Neurological research* 37:77-83.
- Wang S, Yin J, Ge M, Dai Z, Li Y, Si J, Ma K, Li L, Yao S (2016b) Transforming growth-beta 1 contributes to isoflurane postconditioning against cerebral ischemia-reperfusion injury by regulating the c-Jun N-terminal kinase signaling pathway. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie* 78:280-290.
- Wang Y, Reis C, Applegate R, 2nd, Stier G, Martin R, Zhang JH (2015c) Ischemic conditioning-induced endogenous brain protection: Applications pre-, per- or post-stroke. *Experimental neurology* 272:26-40.
- Wechsler LR, Jovin TG (2012) Intravenous recombinant tissue-type plasminogen activator in the extended time window and the US Food and Drug Administration: confused about the time. *Stroke* 43:2517-2519.
- Weir P, Maguire R, O'Sullivan SE, England TJ (2021) A meta-analysis of remote ischaemic conditioning in experimental stroke. *Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism* 41:3-13.
- Wu D et al. (2020) Selective intra-arterial brain cooling improves long-term outcomes in a non-human primate model of embolic stroke: Efficacy depending on reperfusion status. *Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism* 40:1415-1426.
- Yang Z, Chen Y, Zhang Y, Jiang Y, Fang X, Xu J (2014) Sevoflurane postconditioning against cerebral ischemic neuronal injury is abolished in diet-induced obesity: role of brain mitochondrial KATP channels. *Molecular medicine reports* 9:843-850.
- Yin J, Liu X, Wang R, Ge M, Xie L, Zhai J, Dai Z, Li Y, Wang S (2020) Isoflurane Postconditioning Upregulates Phosphorylated Connexin 43 in the Middle Cerebral Artery Occlusion Model and Is Probably Associated with the TGF- β 1/Smad2/3 Signaling Pathway. *BioMed research international* 2020:3451215.
- Yu H, Deng J, Zuo Z (2014) High-fat diet reduces neuroprotection of isoflurane post-treatment: Role of carboxyl-terminal modulator protein-Akt signaling. *Obesity (Silver Spring, Md)* 22:2396-2405.
- Yuan M, Ge M, Yin J, Dai Z, Xie L, Li Y, Liu X, Peng L, Zhang G, Si J, Ma K, Wang S (2018) Isoflurane post-conditioning down-regulates expression of aquaporin 4 in rats with cerebral ischemia/reperfusion injury and is possibly related to bone morphogenetic protein 4/Smad1/5/8 signaling pathway. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie* 97:429-438.
- Zhao H (2007) The protective effect of ischemic postconditioning against ischemic injury: from the heart to the brain. *Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology* 2:313-318.
- Zhu Y, Li S, Liu J, Wen Q, Yu J, Yu L, Xie K (2019) Role of JNK Signaling Pathway in Dexmedetomidine Post-Conditioning-Induced Reduction of the Inflammatory Response and Autophagy Effect of Focal Cerebral Ischemia Reperfusion Injury in Rats. *Inflammation* 42:2181-2191.
- Zhu YM, Gao X, Ni Y, Li W, Kent TA, Qiao SG, Wang C, Xu XX, Zhang HL (2017) Sevoflurane postconditioning attenuates reactive astrogliosis and glial scar formation after ischemia-reperfusion brain injury. *Neuroscience* 356:125-141.